Send us a text

Nick talks to Dr. Berra Yazar-Klosinski, the Chief Science Officer for the Multidisciplinary Association for Psychedelic Studies (MAPS). Berra talked about the results of MAPS' recent Phase III clinical trials for treating severe PTSD, how these studies are conducted, and what we know about the underlying biology of Post-Traumatic Stress Disorder (PTSD) and the drug MDMA.

*Not medical advice.

Support the show

All episodes, show notes, transcripts, and more at the M&M Substack

Affiliates:

KetoCitra—Ketone body BHB + potassium, calcium & magnesium, formulated with kidney health in mind. Use code MIND20 for 20% off any subscription (cancel anytime)
Lumen device to optimize your metabolism for weight loss or athletic performance. Code MIND for 10% off
Readwise: Organize and share what you read. 60 days FREE through link
SiPhox Health—Affordable at-home blood testing. Key health markers, visualized & explained. Code TRIKOMES for a 20% discount.
MASA Chips—delicious tortilla chips made from organic corn & grass-fed beef tallow. No seed oils or artificial ingredients. Code MIND for 20% off

For all the ways you can support my efforts

MDMA (Ecstasy), Post-Traumatic Stress Disorder (PTSD), Psychotherapy & MAPS | Berra Yazar-Klosinski | 26

Mind & Matter

MDMA (Ecstasy), Post-Traumatic Stress Disorder (PTSD), Psychotherapy & MAPS | Berra Yazar-Klosinski | 26